Analyst Ratings For Regeneron Pharmaceuticals (NASDAQ:REGN)
Today, Regeneron Pharmaceuticals (NASDAQ:REGN) stock was downgraded by Canaccord Genuity from Buy to Hold.
Some recent analyst ratings include
- 2/21/2018-Canaccord Genuity was Downgraded by analysts at Canaccord Genuity from a “Buy ” rating to a ” Hold” rating.
- 2/13/2018-BTIG Research Reiterated Rating of Hold.
- 2/9/2018-Robert W. Baird Upgrade from a “Neutral ” rating to a ” Outperform” rating.
Recent Insider Trading Activity For Regeneron Pharmaceuticals (NASDAQ:REGN)
Regeneron Pharmaceuticals (NASDAQ:REGN) has insider ownership of 10.80% and institutional ownership of 64.67%.
- On 2/9/2018 Joseph L Goldstein, Director, sold 1,000 with an average share price of $325.60 per share and the total transaction amounting to $325,600.00.
- On 10/5/2017 Michael S Brown, Director, sold 1,500 with an average share price of $475.00 per share and the total transaction amounting to $712,500.00.
- On 9/29/2017 Charles A Baker, Director, sold 2,000 with an average share price of $450.00 per share and the total transaction amounting to $900,000.00.
- On 9/6/2017 Robert E Landry, SVP, sold 663 with an average share price of $498.60 per share and the total transaction amounting to $330,571.80.
- On 9/5/2017 Robert E Landry, CFO, sold 189 with an average share price of $501.06 per share and the total transaction amounting to $94,700.34.
- On 8/31/2017 Robert E Landry, SVP, sold 427 with an average share price of $493.43 per share and the total transaction amounting to $210,694.61.
- On 8/25/2017 Sanofi, Major Shareholder, bought 72,378 with an average share price of $481.36 per share and the total transaction amounting to $34,839,874.08.
Recent Trading Activity for Regeneron Pharmaceuticals (NASDAQ:REGN)
Shares of Regeneron Pharmaceuticals closed the previous trading session at 318.81 down -4.23 1.31% with 320.54998779296875 shares trading hands.
